New Treatments for Renal Cell Carcinoma: Targeted Therapies

Philip J. Saylor, MD, and M. Dror Michaelson, MD, PhD, Boston, Massachusetts

Key Words
Renal cell carcinoma, tyrosine kinase inhibitors, vascular endothelial growth factor, mammalian target of rapamycin, von Hippel-Lindau, hypoxia inducible factor

Abstract
Systemic treatment options for advanced renal cell carcinoma (RCC) have expanded considerably with the development of targeted therapies. Clear cell RCC commonly features mutation or inactivation of the von Hippel-Lindau gene and resultant overexpression of vascular endothelial growth factor (VEGF). The first drug to validate VEGF as a target in the treatment of clear cell RCC was the monoclonal antibody bevacizumab. Since then, anti-VEGF receptor therapy with multtargeted kinase inhibitors also has shown substantial efficacy. Sunitinib is now a standard first-line therapy for advanced disease and sorafenib is among the second-line treatment options. Other kinase inhibitors are in development. Mammalian target of rapamycin (mTOR) is a second validated therapeutic target as the mTOR inhibitor temsirolimus has been shown to prolong survival in first-line treatment of poor prognosis RCC of all histologies. Everolimus is an oral mTOR inhibitor and has been shown to prolong progression-free survival when used in second-line treatment. Non-clear cell and sarcomatoid RCC are both underrepresented in completed trials but are the subject of active research. Ongoing and planned studies will also evaluate the use of combinations of targeted agents, a strategy that is not advisable outside of clinical trials. Finally, postnephrectomy adjuvant treatment with targeted agents is not yet standard but is under investigation in phase III trials. (JNCCN 2009;7:645–656)

An estimated 54,390 people were diagnosed with cancer of the kidney or renal pelvis in the United States in 2008.1 At diagnosis, 19% had disease that had already spread regionally and 20% had metastatic disease. Approximately 13,010 people with kidney and renal pelvic cancers died in the United States in 2008.

Systemic treatment options for patients who cannot be cured surgically have been limited until recent years. Renal cell carcinoma (RCC) has long been known to respond poorly to cytotoxic chemotherapy.2 Immuno-therapy with cytokines, such as interferon-α or interleukin-2 (IL-2), has shown modest activity at the expense of substantial toxicity.3–6

This article will describe recent advances in the use of targeted therapies for advanced RCC and focus on agents that have been evaluated in published phase III and randomized phase II trials. Sorafenib, sunitinib, everolimus, and temsirolimus have all been FDA-approved to treat advanced RCC. Bevacizumab may soon be approved, and additional targeted agents are in clinical trials.

Although this article does not discuss cytokine therapy, it is important to note that high-dose IL-2 offers measurable complete response and durable remission rates in properly selected patients with advanced disease.7–9 High-dose IL-2 therapy, particularly for patients with a high Karnofsky performance status (> 80) and low-volume or lung-predominant metastatic disease, is a category 2A recommendation by the NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer Panel10 and should be discussed with patients who are appropriate for such consideration.

Cytoreductive nephrectomy before systemic therapy for advanced disease is recommended when feasible because it has been shown to improve survival.10 The trials that established this were conducted when systemic therapy was limited to cytokines.11–13 The role of...
nephrectomy before targeted therapy has not been evaluated in randomized trials.

**Molecular Background**

The study of von Hippel-Lindau (VHL) disease led to much of the current molecular understanding of sporadic RCC. VHL disease is an autosomal dominant syndrome characterized by benign and malignant tumors, such as hemangioblastomas and clear cell RCC. The usual VHL gene product, pVHL, is a tumor suppressor that, as one of its functions, targets several proteins for ubiquitination and proteasomal degradation in the presence of oxygen (see Figure 1). Patients with VHL disease harbor a germline mutation in one allele of the VHL gene. If the second allele is compromised, pVHL function is lost.

First discovered in VHL disease, VHL mutations were later found in many cases of sporadic clear cell RCC. Hypermethylation is a second but less common mechanism for VHL gene inactivation. In one series of 110 sporadic RCC tumors, VHL mutations were detected in 57%. In a similar study (n = 187), VHL mutations were detected in 52% and promoter hypermethylation in 5.3%.

As a consequence of VHL inactivation, clear cell RCC commonly features inappropriate stabilization and accumulation of hypoxia-inducible factor α transcription factors (HIF-1α and -2α). Greater expression of HIF-α transcription factors is associated with increased vascular endothelial growth factor (VEGF) mRNA and protein and increased microvessel density. Recently, HIF-α expression analysis of 160 primary kidney tumors showed 2 distinct patterns among pVHL-deficient tumors: those that express HIF-2α and those that express both HIF-1α and -2α. Those

---

**Figure 1**  Simplified renal cell carcinoma pathways relevant to current targeted therapies.

Abbreviations: EGF, epidermal growth factor; HIFα, hypoxia-inducible factor α; mTOR, mammalian target of rapamycin; O2, oxygen; PDGF, platelet-derived growth factor; pVHL, von Hippel-Lindau protein; TGFα, tumor growth factor α; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

that expressed only HIF-2α displayed elevated c-Myc activity, arguing for a new molecular subclassification among clear cell tumors.

Clear cell–type renal tumors account for 65% to 88% of cases of RCC and have long been observed to be highly vascular. VHL mutations are present in most clear cell RCCs and cause excess downstream secretion of HIF-regulated proteins, such as VEGF. The prevalence of VHL mutations in clear cell RCC therefore led to the investigation of VEGF as a therapeutic target. The first agent to validate this target was bevacizumab, a humanized monoclonal antibody that binds circulating VEGF-A.

**Bevacizumab**

Bevacizumab was studied in a randomized phase II trial of 116 patients with metastatic RCC who had progressed on IL-2. Subjects were randomized to 1 of 3 treatment arms: bevacizumab (10 mg/kg every 2 weeks), low-dose bevacizumab (3 mg/kg), or placebo. The primary end points were time to progression (TTP) and response rate. Interim analysis met the early stopping rule because it showed improved TTP in the higher-dose group relative to placebo (hazard ratio [HR], 2.55; P < .001).

The higher dose (10 mg/kg every 2 weeks) was then combined with cytokine therapy in the first-line phase III AVOREN trial (Table 1). This trial randomized 649 patients with previously untreated metastatic clear cell–predominant RCC to interferon-α (typical dose: 9 MIU subcutaneously, 3 times weekly) with or without bevacizumab. Although the trial was designed to primarily evaluate overall survival, analysis was confounded by the interim development of alternate targeted agents that could be used second-line. The trial was therefore unblinded and progression-free survival became the primary end point. The experimental arm experienced improved progression-free survival (10.2 vs. 5.4 months; P = .0001), fewer progression events (230 vs. 275), and fewer deaths (114 vs. 137), and underwent treatment almost twice as long (9.7 vs. 5.1 months). Fatigue (12%) and anemia (10%) were the most common grade 3 adverse events in the experimental arm (see Table 2).

The similarly-designed CALGB 90206 trial studied interferon-α with or without bevacizumab (10 mg/kg every 2 weeks) for first-line treatment of metastatic clear cell RCC. It was powered to evaluate overall survival and enrolled 732 patients. Overall survival data are pending. The experimental arm experienced superior TTP (8.5 vs. 5.2 months; log rank, P < .0001) and overall response rate (25.5% vs. 13.1%; P < .0001). The experimental arm experienced greater toxicities, most notably the following grade 3 side effects: hypertension (9% vs. 0%), anorexia (17% vs. 8%), fatigue (35% vs. 28%), and proteinuria (13% vs. 0%).

Based on these trials, bevacizumab may soon gain FDA approval for the treatment of RCC. Current practice varies because some clinicians prescribe bevacizumab monotherapy, as used in the phase II National Cancer Institute study, whereas others prescribe the bevacizumab/interferon-α regimen used in both phase III trials. The relative contribution of interferon-α to the efficacy and toxicity of the combination is not defined because bevacizumab has never been compared with bevacizumab/interferon-α in a randomized trial.

**Tyrosine Kinase Inhibition**

**Sorafenib**

The efficacy of bevacizumab, a monoclonal antibody, established VEGF as a therapeutic target in RCC. Since then, most promising agents have been small molecule kinase inhibitors. Sorafenib, an oral inhibitor of VEGF receptors (VEGFR) 1 through 3, platelet-derived growth factor receptor (PDGFR) β, and B-Raf, was the first kinase inhibitor to show benefit in a phase III trial.

The phase III TARGET trial randomized 903 patients with metastatic clear cell RCC who experienced progression on cytokine therapy to oral sorafenib (400 mg, twice daily) or placebo. Although the trial had been designed to evaluate overall survival, planned interim analysis of progression-free survival found the sorafenib arm to be superior (median progression-free survival, 5.5 vs. 2.8 months; HR for progression, 0.44; P < .01). Crossover from placebo to sorafenib was then permitted, potentially confounding survival evaluation. HR for death was 0.72 in the sorafenib arm (95% CI, 0.54–0.94; P = .02), although this was not significant according to the prespecified O’Brien-Fleming threshold for this interim analysis. The response rate to sorafenib was modest but superior to that with placebo (10% vs. 2%; P < .001). Sorafenib is now FDA-approved for the treatment of advanced RCC.
<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Experimental Arms</th>
<th>N</th>
<th>Primary End Point</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVOREN: Previously untreated metastatic RCC, phase III</td>
<td>Bevacizumab + interferon vs. Placebo + interferon</td>
<td>649</td>
<td>OS</td>
<td>PFS superior with bevacizumab: 10.2 vs. 5.4 months; ( P = .0001 )</td>
<td>PFS advantage held regardless of risk group and interferon dose</td>
</tr>
<tr>
<td>CALGB 90206: Previously untreated metastatic clear cell RCC, phase III</td>
<td>Bevacizumab + interferon vs. Placebo + interferon</td>
<td>732</td>
<td>OS</td>
<td>OS data are pending; PFS superior with [bevacizumab + interferon]: 8.5 vs. 5.2 months; log-rank, ( P &lt; .0001 ); Overall response rate superior with [bevacizumab + interferon]: 25.5% vs. 13.1%</td>
<td>Histology had to be predominantly clear cell (&gt; 50%)</td>
</tr>
<tr>
<td>TARGET: Advanced clear cell RCC after cytokine failure, phase III</td>
<td>Sorafenib vs. placebo</td>
<td>903</td>
<td>OS</td>
<td>PFS superior with sorafenib: 5.5 vs. 2.8 months, ( P &lt; .01 ); HR for progression, 0.44 with sorafenib; 95% CI, 0.35–0.55</td>
<td>Overall response rate was low overall but superior with sorafenib (10% vs. 2%)</td>
</tr>
<tr>
<td>Previously untreated advanced clear cell RCC, phase III</td>
<td>Sorafenib vs. interferon</td>
<td>189</td>
<td>PFS</td>
<td>PFS was not significantly changed: 5.7 vs. 5.6 months; PFS after crossover from interferon to sorafenib was 5.3 months; PFS after dose escalation of sorafenib was 3.6 months</td>
<td>When experiencing progression, interferon patients could cross over to sorafenib and sorafenib patients could dose escalate to 600 mg, twice daily</td>
</tr>
<tr>
<td>Previously untreated metastatic RCC, phase III</td>
<td>Sunitinib vs. interferon</td>
<td>750</td>
<td>PFS</td>
<td>PFS superior with sunitinib: 11 vs. 5 months (HR, 0.42; 95% CI, 0.32–0.54); Response rate superior with sunitinib: 31% vs. 6%; ( P &lt; .001 ); OS improved with sunitinib: 26.4 vs. 21.9 months; ( P = .051 )</td>
<td>Patients treated with sunitinib reported significantly improved quality of life (( P &lt; .001 ))</td>
</tr>
<tr>
<td>Global ARCC: Previously untreated poor-prognosis metastatic RCC, phase III</td>
<td>Temsirolimus (25 mg) vs. Temsirolimus (15 mg) + interferon (6 MIU) vs. interferon (3 MIU, increased to 18 MIU)</td>
<td>626</td>
<td>OS</td>
<td>OS was superior with temsirolimus than with interferon: 10.9 vs. 7.3 months; ( P &lt; .001 ); PFS was also superior; ( P &lt; .001 )</td>
<td>All histologies were included; OS did not differ between combination and interferon groups</td>
</tr>
<tr>
<td>RECORD-1: Metastatic clear cell RCC which had progressed on VEGF-targeted therapy, phase III</td>
<td>Everolimus (n = 272) vs. placebo (n = 138)</td>
<td>410</td>
<td>PFS</td>
<td>PFS superior with everolimus: 4.0 vs. 1.9 months; HR for progression, 0.30; 95% CI, 0.22–0.40</td>
<td>Temsirolimus was the only excluded prior targeted therapy</td>
</tr>
</tbody>
</table>

Abbreviations: ARCC, Advanced Renal Cell Carcinoma; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma; TARGET, Treatment Approaches in RCC Global Evaluation Trial; VEGF, vascular endothelial growth factor.

Note: Unless otherwise specified, doses are as follows: bevacizumab (10 mg/kg intravenously, every 2 weeks), interferon \( \alpha \)-2a (9 MIU subcutaneously, 3 times weekly), sorafenib (400 mg orally, twice daily), sunitinib (50 mg, once daily for 4 weeks followed by 2 weeks without treatment), temsirolimus (25 mg intravenously, once weekly), and everolimus (10 mg, once daily).
<table>
<thead>
<tr>
<th>Drug target(s)</th>
<th>Bevacizumab + Interferon</th>
<th>Sorafenib</th>
<th>Sunitinib</th>
<th>Axitinib</th>
<th>Temsirolimus</th>
<th>Everolimus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism</strong></td>
<td>mAb</td>
<td>kinase inhibitor</td>
<td>TKI</td>
<td>TKI</td>
<td>Allosteric inhibitor of mTOR kinase</td>
<td>Allosteric inhibitor of mTOR kinase</td>
</tr>
<tr>
<td><strong>Drug target(s)</strong></td>
<td>VEGF</td>
<td>VEGFR-2, FLT3, PDGFR, FGFR1, C-raf, B-Raf</td>
<td>VEGFR, PDGFR, c-kit</td>
<td>VEGFR-1, -2, -3</td>
<td>mTOR</td>
<td>mTOR</td>
</tr>
<tr>
<td><strong>Fatigue</strong></td>
<td>12 (33)</td>
<td>5 (37)</td>
<td>7 (51)</td>
<td>8 (54)</td>
<td>3 (20)</td>
<td></td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>3 (26)</td>
<td>4 (17)</td>
<td>8 (24)</td>
<td>15 (60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diarrhea</strong></td>
<td>2 (20)</td>
<td>2 (43)</td>
<td>5 (53)</td>
<td>10 (62)</td>
<td>1 (27)</td>
<td>1 (17)</td>
</tr>
<tr>
<td><strong>Hand/foot skin reaction</strong></td>
<td>6 (30)</td>
<td>5 (20)</td>
<td>0 (12) abdomen; 1 (11) limb; 1 (5) myalgia</td>
<td>4 (21) abdomen; 5 (28) any; 3 (20) back</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td>2 (11) abdomen; 1 (8) bone; 2 (10) joint; 3 (6) tumor</td>
<td>1 (11) limb; 0 (12) abdomen; 0 (14) arthralgia; 4 (20) limb; 2 (12) myalgia</td>
<td>4 (21) abdomen; 5 (28) any; 3 (20) back</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Asthenia</strong></td>
<td>10 (32)</td>
<td>4 (17)</td>
<td>11 (51)</td>
<td>1 (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dyspnea</strong></td>
<td>&lt; 1 (13)</td>
<td>4 (14)</td>
<td>9 (28)</td>
<td>1 (8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infection</strong></td>
<td>5 (27)</td>
<td>3 (10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anemia</strong></td>
<td>3 (10)</td>
<td>3 (8)</td>
<td>4 (71)</td>
<td>20 (45)</td>
<td>9 (91)</td>
<td></td>
</tr>
<tr>
<td><strong>Leukopenia</strong></td>
<td>5 (78)</td>
<td>1 (6)</td>
<td>0 (26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>4 (7)</td>
<td>5 (18)</td>
<td>12 (72)</td>
<td>3 (7)</td>
<td>0 (11)</td>
<td></td>
</tr>
<tr>
<td><strong>Lymphopenia</strong></td>
<td>13</td>
<td>12 (60)</td>
<td>15 (42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Elevated uric acid</strong></td>
<td>0 (12) abdomen; 0 (14) arthralgia; 4 (20) limb; 2 (12) myalgia</td>
<td>4 (21) abdomen; 5 (28) any; 3 (20) back</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Elevated lipase</strong></td>
<td>12 (41)</td>
<td>16 (52)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Elevated amylase</strong></td>
<td>5 (32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hyperglycemia</strong></td>
<td>11 (26)</td>
<td>12 (50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thrombocytopenia</strong></td>
<td>2 (6)</td>
<td>1 (12)</td>
<td>8 (65)</td>
<td>1 (14)</td>
<td>&lt; 1 (20)</td>
<td></td>
</tr>
<tr>
<td><strong>Proteinuria</strong></td>
<td>7 (18)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypophosphatemia</strong></td>
<td>13</td>
<td>5 (36)</td>
<td>4 (32)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: mAb, monoclonal antibody; FGFR1, fibroblast growth factor receptor-1; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; TKI, small molecule tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

*All dosing is typical.

†Listed are all toxicities that are experienced as higher than grade 3 by at least 5% of patients in any of the cited trials. Numbers are expressed as the percentage of patients experiencing grade 3 to 4 toxicity (percentage experiencing any-grade toxicity in parentheses).
The most prominent adverse events with sorafenib were diarrhea, rash, fatigue, and hand–foot skin reactions (Table 2). Rare hypertension, cardiac ischemia, and acute coronary syndromes were also noted. The incidence of cardiac ischemia/infarction was 2.9% with sorafenib and 0.4% with placebo.

A phase II trial that tested sorafenib as first-line therapy for metastatic RCC randomized 189 patients with advanced RCC to either sorafenib (400 mg, twice daily) or interferon-α. The study did not meet its primary end point because progression-free survival was similar in the sorafenib and interferon-α groups (5.7 vs. 5.6 months, respectively). The response rate was less than 10% in both arms. Rash and diarrhea were more common with sorafenib, whereas flu-like symptoms were more common with interferon-α. Based on this trial, first-line sorafenib at standard doses seems to offer no advantage over first-line cytokine therapy.

**Sunitinib**

The current first-line standard of care for patients with good- or intermediate-risk advanced clear cell RCC is sunitinib, a drug that inhibits PDGFR-α and -β, VEGFRs -1 through -3, stem cell factor receptor (c-KIT), FMS-like tyrosine kinase, colony-stimulating factor, and neurotrophic factor receptor.

After showing unprecedented activity in single arm trials, sunitinib was compared with interferon-α as first-line treatment of advanced clear cell RCC in a phase III trial. This trial randomized 750 patients to either interferon-α or sunitinib (50 mg orally, once daily for 4 weeks followed by 2 weeks rest). The groups were well balanced because each had fewer than 10% of patients with poor-risk disease by Memorial Sloan-Kettering Cancer Center (MSKCC) criteria. The primary end point, median progression-free survival, was improved in the sunitinib arm (11 vs. 5 months; HR for progression, 0.42; P < .001), as was objective response rate (31% vs. 6%).

Grade 3 or higher treatment-related fatigue was more common with interferon-α, although diarrhea was more common with sunitinib (Table 2). Treatment-related quality of life, assessed by 2 validated questionnaires (FACT-G [Functional Assessment of Cancer Therapy: General], Fksi [Functional Assessment of Cancer Treatment: Kidney Index]), was better in the sunitinib group (P < .001). Mature data have since been presented and suggest improved overall survival in the sunitinib arm (26.4 vs. 21.8 months; P = .051). This trial provides evidence supporting sunitinib as first-line therapy for good- and intermediate-risk advanced clear cell RCC. Sunitinib is FDA-approved.

**Toxicities**

Common side effects of VEGF-targeted therapies for RCC include fatigue, hypertension, diarrhea, skin toxicity, and others (Table 2). Three toxicities that deserve specific mention are hypothyroidism, cardiac toxicity, and hand–foot skin toxicity.

Fatigue is a prominent side effect of sunitinib, with an incidence of more than 50%. Hypothyroidism is sometimes the underlying cause. In one series, 66 patients treated with sunitinib had also been evaluated with thyroid function tests. Of those 66 subjects, 56 (85%) had at least 1 thyroid function laboratory abnormality, most commonly elevated thyroid-stimulating hormone with low T3. In that series, all laboratory abnormalities normalized with thyroid hormone supplementation. Although routine monitoring of thyroid function is rational, no standard of care has been defined. Clinical monitoring throughout treatment is appropriate.

Cardiotoxicity has been thoroughly studied with sunitinib treatment. In a retrospective review of 75 patients treated with sunitinib, a composite of cardiovascular events (cardiac death, myocardial infarction, and congestive heart failure) occurred in 8 (11%). Two sunitinib trials prospectively examined left ventricular ejection fraction (LVEF). In one, the incidence of grade 3 decline after 6 months was similar in the sunitinib and interferon-α arms (2% vs. 1%). All declines were reversible with discontinuation or dose reduction. In another trial (n = 207), LVEF measured at baseline and day 28 of each treatment cycle did not show a decrease. Outside of trials, it is reasonable to obtain a baseline echocardiogram in patients at risk for congestive heart failure and to clinically monitor all patients for related signs and symptoms.

Tenderness/pain, erythema, blistering, and scaling of the finger tips, palms, and soles have been commonly observed with sorafenib and sunitinib and can substantially affect quality of life. This toxicity may develop within the first 2 to 4 weeks of therapy and particularly affects points of weight-bearing or flexure. Its reported incidence has ranged from 9% to as high as 62%. The incidence of grade 3 toxicity is 5% to 6%. Evidence-based recommendations...
for managing this toxicity are absent. Dose reduction or temporary stoppage is often advisable. Careful choice of footwear and avoidance of excessive friction or hot water can be preventative measures.\textsuperscript{32} Moisturizers and keratolytics (e.g., 20\%–40\% urea cream) are reasonable. Topical steroids and analgesics can be considered in more severe cases.

**Pazopanib**

Pazopanib is an experimental kinase inhibitor that targets VEGFR-1 to -3, PDGFR-\(\alpha\) and -\(\beta\), and c-Kit. Daily oral pazopanib was evaluated in a randomized, placebo-controlled phase II trial\textsuperscript{41} that enrolled patients with advanced RCC that was treatment naïve (67\%) or refractory to one prior cytotoxic and/or bevacizumab-containing regimen (33\%). Analysis of the first 60 patients treated with pazopanib showed a partial response rate of 40\% (\(n = 24\)) and stable disease of 42\% (\(n = 25\)). The rate of grade 3 or 4 adverse events was 26\%, with the most prominent being hypertension (8\%) and alanine aminotransferase elevation (8\%). Common lower-grade toxicities included diarrhea, fatigue, nausea, and hair depigmentation. Updated 12-week response rate (\(n = 225\)) was later reported to be a more modest 27\%.\textsuperscript{44}

Pazopanib is now being studied in 2 randomized phase III trials (Table 3). The first is testing it against placebo for the second-line treatment of advanced clear cell RCC after cytokine failure, whereas the second is comparing it with sunitinib for the first-line treatment of advanced clear cell RCC. Pazopanib is not FDA-approved.

**Axitinib**

Axitinib is a selective oral inhibitor of VEGFR-1 through -3. It was studied in a single-arm phase II trial for patients with metastatic cytokine-refractory disease (\(n = 52\)).\textsuperscript{49} The response rate was 44.2\% (2 complete responses, 21 partial responses). Median TTP and overall survival were 15.7 and 29.9 months, respectively. Adverse events included diarrhea, fatigue, hypertension, nausea, and hoarseness. The rate of treatment-related hypertension was 58\% (\(n = 30\)), although most cases were controlled with antihypertensives. Subsequent studies have correlated treatment-related hypertension with efficacy, and a planned phase II trial will titrate the dose to development of hypertension. A phase III trial of second-line therapy for metastatic disease is comparing axitinib with sorafenib (Table 3). Axitinib is not FDA approved.

**Mammalian Target of Rapamycin Inhibition**

**Temsirolimus**

Mammalian target of rapamycin (mTOR) kinase is thought to be important to cellular growth and proliferation because it mediates a growth factor receptor pathway downstream of phosphatidyloinositol 3-kinase and AKT.\textsuperscript{46} It has become a validated target for the treatment of RCC, with 2 rapamycin derivatives (temsirolimus, everolimus) gaining FDA approval. Both rapamycin analogs are competitive inhibitors of mTOR kinase.

Temsirolimus, a specific inhibitor of mTOR, was evaluated in the phase III Advanced Renal Cell Carcinoma (ARCC) trial,\textsuperscript{47} involving 626 patients with poor-prognosis, previously untreated metastatic RCC of various histologic types. The definition of poor prognosis in this trial was a modified version of the widely used MSKCC criteria. MSKCC defines poor-risk patients as having 3 or more of the following 5 pretreatment features: low Karnofsky performance status, high lactate dehydrogenase, low hemoglobin, high corrected serum calcium, and less than 1 year from diagnosis to the start of therapy.\textsuperscript{36} The ARCC trial added a sixth risk factor: metastases in multiple organs. Because multiple organs were involved in 80\% of the enrolled patients, some patients met poor-risk criteria only according to this modified definition.

Patients were randomized among 3 arms: interferon-\(\alpha\) monotherapy, combination therapy using interferon-\(\alpha\) and 15 mg weekly temsirolimus, or monotherapy with 25 mg of weekly temsirolimus. The primary end point was survival. Overall survival (HR for death, 0.73; \(P = .008\)) and progression-free survival (\(P < .001\)) were improved with temsirolimus alone compared with interferon-\(\alpha\) alone. No survival benefit was seen in the combination arm compared with the interferon arm. Median overall survival was 10.9 months with temsirolimus, 8.4 months with combination therapy, and 7.3 months with interferon-\(\alpha\). The most common adverse effects of temsirolimus were rash, peripheral edema, hyperglycemia, and hyperlipidemia (see Table 2). Based on this study, temsirolimus was FDA-approved for treating advanced RCC and is an appropriate first-line treatment for poor-prognosis RCC of any histology.
<table>
<thead>
<tr>
<th>Clinical Setting/Phase</th>
<th>Experimental Arms</th>
<th>Sponsor</th>
<th>Target Enrollment</th>
<th>Primary End Point</th>
<th>Comments/Status</th>
<th>ClinicalTrials.gov Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>BeST trial, first-line metastatic clear cell RCC; randomized phase II</td>
<td>Four arms: • Bevacizumab • Sorafenib/bevacizumab • Sorafenib/temsirolimus • Temsirolimus/bevacizumab</td>
<td>NCI, ECOG</td>
<td>360 (90/arm); opened 9/07, recruiting</td>
<td>PFS</td>
<td>Combination targeted therapy; 1 prior vaccine or cytokine therapy is permitted</td>
<td>NCT00378703</td>
</tr>
<tr>
<td>First-line locally advanced and/or metastatic; phase III noninferiority</td>
<td>Pazopanib vs. sunitinib (1:1 randomization)</td>
<td>GSK</td>
<td>876; opened 8/08, recruiting</td>
<td>PFS</td>
<td>Must have clear cell component histology; no prior systemic treatment</td>
<td>NCT00720941</td>
</tr>
<tr>
<td>TORAVA trial, first-line metastatic; randomized phase II</td>
<td>Three arms (2:1:1 randomization): • Temsirolimus/bevacizumab • IFN/bevacizumab • Sunitinib</td>
<td>Centre Leon Berard, Wyeth</td>
<td>160; opened 2/08, recruiting</td>
<td>Progression-free rate at 48 weeks posttreatment</td>
<td>All histologies except papillary; no prior systemic treatment; open only in France</td>
<td>NCT00619268</td>
</tr>
<tr>
<td>Second-line; phase III</td>
<td>Everolimus/placebo vs. Everolimus/bevacizumab</td>
<td>NCI: CALGB</td>
<td>Planned</td>
<td>(Not yet open)</td>
<td>Planned</td>
<td>(Not yet open)</td>
</tr>
<tr>
<td>Locally advanced and/or metastatic after cytokine failure; phase III</td>
<td>Pazopanib vs. placebo (2:1 randomization)</td>
<td>GSK</td>
<td>400; opened 4/06, active but not recruiting</td>
<td>PFS</td>
<td>Must be clear cell predominant; prior angiogenesis targeted therapy not permitted</td>
<td>NCT00334282</td>
</tr>
<tr>
<td>First-line metastatic clear cell; randomized phase II</td>
<td>Everolimus/bevacizumab vs. IFN/bevacizumab</td>
<td>Novartis</td>
<td>360; opened 8/08, recruiting</td>
<td>PFS</td>
<td>Will continue until 230 PFS events have occurred</td>
<td>NCT00719264</td>
</tr>
<tr>
<td>AXIS trial, second-line metastatic; phase III</td>
<td>Axitinib vs. sorafenib (1:1 randomization)</td>
<td>Pfizer</td>
<td>540; opened 7/08, recruiting</td>
<td>PFS</td>
<td>Must have component of clear cell; 1 prior systemic first-line regimen</td>
<td>NCT00678392</td>
</tr>
<tr>
<td>First-line metastatic; phase III</td>
<td>Temsirolimus/bevacizumab vs. IFN/bevacizumab</td>
<td>Wyeth</td>
<td>800; opened 3/08, recruiting</td>
<td>PFS</td>
<td>Must have majority component of clear cell</td>
<td>NCT00631371</td>
</tr>
<tr>
<td>Second-line metastatic after sunitinib failure; phase III</td>
<td>Temsiroimls vs. sorafenib</td>
<td>Wyeth</td>
<td>480; opened 7/07, recruiting</td>
<td>PFS</td>
<td>All histologies accepted; nephrectomy not required</td>
<td>NCT00474786</td>
</tr>
</tbody>
</table>

Abbreviations: GSK, GlaxoSmithKline; IFN, interferon; NCI, National Cancer Institute; PFS, progression-free survival; RCC, renal cell carcinoma.
Everolimus

Everolimus is an oral mTOR inhibitor that is mechanistically similar to temsirolimus. Activity in an early-phase study led to a phase III trial for metastatic clear cell RCC that progressed on VEGF-targeted therapy. Subjects were randomized 2:1 to everolimus (10 mg, daily) or placebo, with progression-free survival the primary end point. The second interim analysis after 191 progression events showed superior results in the everolimus arm, and the study was halted. Progression-free survival (HR, 0.30; \( P < .0001; \) median progression-free survival, 4.0 vs. 1.9 months) was improved with everolimus. Common toxicities are detailed in Table 2. Significant side effects included stomatitis (40%), rash (25%), and fatigue (20%). Notably, 8% of everolimus patients experienced pneumonitis, with approximately a third grade 3.

Based on its modest but clearly observed progression-free survival benefit, everolimus is a reasonable choice for second-line therapy and has gained FDA approval.

Epidermal Growth Factor Receptor Targeted Therapy

Epidermal growth factor receptor (EGFR) is overexpressed in most RCC cases and associated with the presence of metastases. Tumor blood vessels also commonly stain positive for its ligand, transforming growth factor-\( \alpha \). Although EGFR-targeted therapy is a rational approach for RCC and has shown promise in preclinical study, it has thus far been clinically unsuccessful. One example is lapatinib, a tyrosine kinase inhibitor of EGFR and human epidermal growth factor receptor 2 (HER-2). A phase III trial for advanced RCC (n = 416) that compared lapatinib, 1250 mg daily, with hormone therapy (tamoxifen or megestrol acetate) showed that TTP did not differ between arms (15.3 vs. 15.4 weeks). Among patients with EGFR overexpression according to immunohistochemistry (n = 241), TTP was marginally improved (15.1 vs. 10.9 weeks; HR, 0.76; \( P = .06 \)).

Non-Clear Cell RCC

Treatment options for non-clear cell RCC are not yet well defined. Non-clear cell histologies represent 15% to 20% of all RCC. Papillary RCC accounts for approximately 80% of these and is followed by chromophobe, collecting duct, unclassified, and medullary carcinomas.

The rationale for VEGF-targeted treatment for non-clear cell RCC is uncertain. In theory, VEGF inhibition is used to counteract the effects of the VHL gene inactivation commonly seen only in clear cell RCC. Small retrospective analyses of non-clear cell RCC treated with sunitinib or sorafenib have reported low response rates. Most of the previously mentioned clinical trials have limited enrollment to clear cell RCC. The phase III trial of temsirolimus is a notable exception, as 124 of 626 patients (19.8%) had non-clear cell disease. When temsirolimus (n = 37) was compared with interferon-\( \alpha \) (n = 36) in that subset, overall survival (11.6 vs. 4.3 months) and progression-free survival (7.0 vs. 1.8 months) were strikingly better with temsirolimus.

The study of hereditary papillary renal carcinoma (HPRC) has led to molecular insights about papillary RCC. HPRC is caused by a germline mutation in the tyrosine kinase domain of the c-MET proto-oncogene and associated with multifocal papillary RCC. Some sporadic papillary RCC also features activating MET mutations, with one series showing this in 17 of 129 (13%) patients. MET inhibitors are in development and can be considered for patients with papillary renal carcinomas that harbor MET mutations. One open phase II study uses a c-MET kinase inhibitor (GSK1363089; formerly XL880).

Although temsirolimus and VEGF-targeted therapies both have low objective response rates in non-clear cell RCC, temsirolimus was shown to confer an overall survival benefit in the phase III ARCC trial. Given these data, temsirolimus is a reasonable first-line treatment for patients with advanced non-clear cell RCC. Prospective trials of other targeted therapies are needed for this subset of patients.

Sarcomatoid RCC

The spindle-shaped cells characteristic of sarcomatoid differentiation can be a feature of any common subtype of RCC (clear cell, papillary, chromophobe) and are found in 1% to 8% of cases overall. Sarcomatoid differentiation is associated with aggressive tumor biology, early metastasis, and poor prognosis. One retrospective review suggested that responses to VEGF-targeted therapy were limited to those with clear cell histology and fewer than...
20% sarcomatoid elements. Although sarcomatoid RCC is more responsive to cytotoxic chemotherapy than other subtypes of RCC, response rates are modest. The combination of doxorubicin and gemcitabine is currently in a phase II cooperative group study. Two current phase II trials are examining the combination of cytotoxic chemotherapy with targeted therapy in the form of sunitinib/gemcitabine and capecitabine/gemcitabine/bevacizumab.

Integration of Existing Targeted Therapies

Because evidence-based integration of targeted therapies for RCC is in its infancy, clinical trial participation is always encouraged. Recently completed clinical trials using targeted therapies have not directly compared them with each other. Nonetheless, some conclusions can be made.

Sunitinib is the standard first-line agent for most patients with advanced clear cell RCC based on its clear progression-free survival benefit. Temsirolimus prolongs survival in poor-risk disease of any histology and can reasonably be used as first-line therapy for patients who have clear cell RCC with 3 or more risk factors according to the modified criteria used in that trial, or those who have non-clear cell RCC. Sunitinib and sorafenib are both reasonable first-line choices for non-clear cell RCC but are supported by a lower level of evidence than temsirolimus.

After patients experience progression on first-line therapy, everolimus and sorafenib improve progression-free survival. Sunitinib and temsirolimus are also reasonable choices when they have not already been used in the first-line setting. The choice of second-line therapy can reasonably be shaped by an effort to use an agent that is mechanistically distinct from the first-line agent, although no data are available for this practice.

Bevacizumab/interferon-α combination is a reasonable choice for first-line treatment of clear cell RCC, but application of the clinical trial data has 2 limitations. First, the phase III trials have enrolled only previously untreated patients, and second, interferon-α contributes to side effects but is of uncertain added value. Bevacizumab monotherapy is a reasonable strategy but has only been tested in a phase II study.

Future Directions

Combination Therapy

Targeted agents generally have not been combined in completed trials. This is beginning to change; combination therapy is currently under investigation in several notable trials (Table 3). Among the combinations are sorafenib/bevacizumab, sorafenib/temsirolimus, temsirolimus/bevacizumab, and everolimus/bevacizumab.

In the second-line setting, whether the first-line treatment should be replaced or added to is not yet clear. These issues can only be answered by prospective trials. No combination of targeted therapies should be used outside of clinical trials.

Adjuvant Therapy

Current standard care for fully resected RCC is observation, regardless of relapse risk. Given the efficacy of targeted therapy in the advanced setting, investigators are studying systemic treatment for preventing relapse after surgery for localized RCC. Adjuvant sunitinib and sorafenib are being compared in a 3-arm, randomized, placebo-controlled trial for preventing relapse after nephrectomy. The trial is powered to examine disease-free survival and was designed to enroll 1332 patients. Enrollment has completed in another placebo-controlled phase III adjuvant trial using cG250, a monoclonal antibody to the MN surface antigen present in clear cell cancer. These and future studies may identify a role for targeted therapy in not only treating advanced RCC, but also preventing relapse after localized therapy.

References


Saylor and Michaelson